Simple Summary The estimated survival time for glioblastoma patients is extremely low; only
about 5% of patients survive five years post diagnosis. The standard of care for glioblastoma …

Despite aggressive multimodal treatment, glioblastoma (GBM), a grade IV primary brain
tumor, still portends a poor prognosis with a median overall survival of 12–16 months. The …

Glioblastoma multiforme (GBM) is an incurable form of brain cancer with a very poor
prognosis. Because of its highly invasive nature, it is impossible to remove all tumor cells …

Glioblastoma multiforme (GBM) is the most common brain tumor with very aggressive and
infiltrative. Extracellular matrix (ECM) plays pivotal roles in the infiltrative characteristics of …

Activation of nuclear factor κB (NF-κB) induces mesenchymal (MES) transdifferentiation and
radioresistance in glioma stem cells (GSCs), but molecular mechanisms for NF-κB activation …

Glioblastoma is a highly aggressive brain tumor that is characterized by its unparalleled
invasiveness. Invasive glioblastoma cells not only escape surgery and focal therapies but …

CD90 is a membrane GPI-anchored protein with one Ig V-type superfamily domain that was
initially described in mouse T cells. Besides the specific expression pattern and functions of …

Background Glioblastoma (GBM) remains a largely incurable disease as current therapy
fails to target the invasive nature of glioma growth in disease progression and recurrence …

Endoplasmic reticulum (ER) proteostasis is often altered in tumor cells due to intrinsic
(oncogene expression, aneuploidy) and extrinsic (environmental) challenges. ER stress …

Gliomas are the most common primary brain tumors and have a very dismal prognosis.
However, recent advancements in nanomedicine and nanotechnology provide opportunities …